ABBOTT PARK, Ill., Aug. 13 /PRNewswire-FirstCall/ -- Abbott today announced the expansion of the company's XIENCE V® USA post-approval study designed to evaluate the safety and effectiveness of the company's market-leading XIENCE V® Everolimus Eluting Coronary Stent System in a real-world clinical setting out to five years. The expansion allows for more than 2,000 patients from the XIENCE V USA trial to be eligible to cross over into the landmark Dual Anti-Platelet Therapy (DAPT) Trial, an industry-wide collaboration with medical device and pharmaceutical companies.
